Sign In
Buy PRAX
$314.56
-10.43 (-3.21%)
At Close: Jul 13, 2026
Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route Potential to expand the addressable market for ulixacaltamide beyond the initial patien
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Thursday, 02'nd Jul 2026
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, to
FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) pr
Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results
01:27pm, Monday, 22'nd Jun 2026
Praxis Precision Medicines Inc. (NASDAQ:PRAX) said on Monday that the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to elsunersen (PRAX-222), its investigational therapy f
The Breakthrough Therapy Designation (BTD) was granted based on the positive results from the EMBRAVE Part A trial of elsunersen Elsunersen demonstrated a 77% sham-adjusted reduction in monthly seizur
Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
04:38pm, Monday, 08'th Jun 2026
Praxis Precision Medicines, Inc. (PRAX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Praxis' Premium Price May Reflect Unrealistic Market Prospects In Essential Tremor
03:23pm, Friday, 05'th Jun 2026
Praxis Precision Medicines, Inc. is valued as a pure-play on ulixacaltamide's commercial launch in essential tremor, with pipeline optionality limited. I maintain a cautious Hold rating, as PRAX trade
Praxis Precision Medicines to Participate in Goldmans Sachs 47th Annual Global Healthcare Conference
04:01pm, Thursday, 04'th Jun 2026
BOSTON, June 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, to
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 02'nd Jun 2026
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, to
Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint
06:09am, Tuesday, 02'nd Jun 2026
Praxis Precision Medicines Inc. (NASDAQ:PRAX) on Monday reported results from its Phase 2/3 POWER1 study of vormatrigine for focal onset seizures.
Praxis Precision's epilepsy drug misses main goal of mid-to-late stage study
06:11pm, Monday, 01'st Jun 2026
Praxis Precision Medicines said on Monday its experimental epilepsy drug failed to meet the main goal of a mid- to late-stage study, prompting it to pause enrollment in another ongoing study whi
Praxis Precision Medicines Provides Vormatrigine Program Update
04:15pm, Monday, 01'st Jun 2026
POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second
Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
09:30pm, Tuesday, 12'th May 2026
Praxis Precision Medicines, Inc. (PRAX) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript
01:21pm, Saturday, 09'th May 2026
Praxis Precision Medicines, Inc. (PRAX) Q1 2026 Earnings Call Transcript
Praxis Precision Medicines Q1 Earnings Call Highlights
04:15pm, Friday, 08'th May 2026
Praxis Precision Medicines NASDAQ: PRAX said it is preparing for two potential U.S. product launches while advancing several late-stage clinical programs, as management outlined first-quarter 2026 res
